SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

Astellas Pharma is digging up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease—but the genetic medicines company is going to have to wait a ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the ...

6 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

Intravitreal 4D-150 was well-tolerated with no inflammation in 14 of 15 patients and only trace mixed cells at a single timepoint in one patient; no dose-limiting toxicities, treatment-related serious ...

In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...

Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one ...